 |
|
|
| |
First-in-Human Trial of MK-8591-Eluting Implants Demonstrates
Concentrations Suitable for
HIV Prophylaxis for at Least
One Year
|
| |
| |
10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City
Randolph Matthews, MD, PhD
Sr. Principal Scientist
Translational Pharmacology, Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
